From: Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy
Well-nourished (n = 69) | Bad-nourished (n = 39) | p value | |
---|---|---|---|
Age (median, range) | 63 (34–83) | 66 (36–80) | 0.67 |
Gender (male) | 38 | 20 | 0.7 |
WHO performance status (> 2) | 6 (8.7%) | 11 (28.2) | < 0.01 |
Body mass index (median, range) | 24.1 (18.6–33.8) | 23.1 (13.3–28.8) | 0.47 |
Primary site | |||
Rectum | 23 | 10 | 0.4 |
Right-sided (n = 51) | 27 | 24 | 0.03 |
Left-sided (n = 57) | 40 | 17 | 0.15 |
Residual of primary tumor | 12 | 5 | 0.53 |
First line regimen | |||
FOLFOX/FOLFIRI | 19/56 | 11/22 | 0.94 |
Add-on targeting agent | |||
VEGFR (n = 41) | 30 (43.5%) | 11 (28.2%) | 0.11 |
EGFR (n = 38) | 26 (37.7%) | 12 (30.8%) | 0.47 |
None (n = 29) | 13 (18.8%) | 16 (41.0%) | 0.01 |
Adverse eventa | |||
Hematotoxicity | |||
Grade 2 | 13 (18.8%) | 12 (30.8%) | 0.11 |
Grade 3 | 4 (5.8%) | 4 (10.3%) | 0.39 |
Grade 4 | 0 (0%) | 1 (2.6%) | 0.18 |
Non-hematotoxicity | |||
Grade 2 | 11 (15.9%) | 15 (38.5%) | < 0.01 |
Grade 3 | 7 (10.1%) | 6 (15.4%) | 0.42 |
Grade 4 | 1 (1.4%) | 0 (0%) | 0.68 |
Tumor markerb | |||
CEA | 16.8 (3.7–45.1) | 6.9 (2.9–14.4) | 0.39 |
CA19-9 | 19.6 (2.3–46.9) | 15.6 (6.9–81.2) | 0.19 |